Huang J, Chan SC, Lok V, Zhang L, Lucero-Prisno DE 3rd, Xu W, et al. The epidemiological landscape of multiple myeloma: a global cancer registry estimate of disease burden, risk factors, and temporal trends. Lancet Haematol. 2022;9(9):e670–7.

Article  CAS  PubMed  Google Scholar 

Zhu DT, Lai PA, Zhang L, Attar H, Rebbeck TR. Multiple myeloma incidence and mortality trends in the United States, 1999–2020. Sci Rep. 2024;14(1):14564.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Dimopoulos MA, Terpos E, Boccadoro M, Moreau P, Mateos MV, Zweegman S, et al. EHA-EMN evidence-based guidelines for diagnosis, treatment and follow-up of patients with multiple myeloma. Nat Rev Clin Oncol. 2025;22(9):680–700.

Article  PubMed  Google Scholar 

Mateos MV, Weisel K, De Stefano V, Goldschmidt H, Delforge M, Mohty M, et al. LocoMMotion: a prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed and/or refractory multiple myeloma. Leukemia. 2022;36(5):1371–6.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Franco A, Damdinsuren B, Ise T, Dement-Brown J, Li H, Nagata S, et al. Human Fc receptor-like 5 binds intact IgG via mechanisms distinct from those of Fc receptors. J Immunol. 2013;190(11):5739–46.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Trudel S, Cohen AD, Krishnan AY, Fonseca R, Spencer A, Berdeja JG, et al. Cevostamab monotherapy continues to show clinically meaningful activity and manageable safety in patients with heavily pre-treated relapsed/refractory multiple myeloma (RRMM): updated results from an ongoing phase I study. Blood. 2021;138(Suppl. 1):157.

Article  Google Scholar 

Cohen AD, Trudel S, Forsberg P, Fonseca R, Krishnan A, Spencer A, et al. GO39775: a multicenter phase I trial evaluating the safety, pharmacokinetics, and activity of BFCR4350A, a FcRH5/CD3 T-cell dependent bispecific antibody, in patients with relapsed or refractory multiple myeloma. J Clin Oncol. 2020;38(15_Suppl.):TPS8551.

Richter J, Thomas SK, Krishnan AY, Laubach JP, Cohen AD, Trudel S, et al. Cevostamab in patients with heavily pretreated relapsed/refractory multiple myeloma (RRMM): updated results from an ongoing phase I study demonstrate clinically meaningful activity and manageable safety and inform the doses and regimen for combination studies. Blood. 2024;144(Suppl. 1):1021.

Article  Google Scholar 

Delforge M, Richter J, Cohen YC, Corradini P, Sborov DW, Lesokhin AM, et al. Biomarker correlates and clinical activity of cevostamab in patients (pts) with triple-class refractory multiple myeloma (MM) who have received ≥1 prior B-cell maturation antigen (BCMA)-targeted bispecific antibody (BsAb): results from the phase I/II CAMMA 2 study. Blood. 2024;144(Suppl. 1):4732.

Article  Google Scholar 

Kumar S, Bachier CR, Cavo M, Corradini P, Delforge M, Janowski W, et al. CAMMA 2: a phase I/II trial evaluating the efficacy and safety of cevostamab in patients with relapsed/refractory multiple myeloma (RRMM) who have triple-class refractory disease and have received a prior anti-B-cell maturation antigen (BCMA) agent. J Clin Oncol. 2023;41(16_Suppl.):TPS8064.

Marella M, Yao X, Carreira V, Bustamante MF, Clark HB, Jackson CC, et al. Comprehensive BCMA expression profiling in adult normal human brain suggests a low risk of on-target neurotoxicity in BCMA-targeting multiple myeloma therapy. J Histochem Cytochem. 2022;70(4):273–87.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Van Oekelen O, Aleman A, Upadhyaya B, Schnakenberg S, Madduri D, Gavane S, et al. Neurocognitive and hypokinetic movement disorder with features of parkinsonism after BCMA-targeting CAR-T cell therapy. Nat Med. 2021;27(12):2099–103.

Article  PubMed  PubMed Central  Google Scholar 

Guo P, Wang Y, He H, Chen D, Liu J, Qiang W, et al. Elevated serum levels of soluble B-cell maturation antigen as a prognostic biomarker for multiple myeloma. Clin Exp Immunol. 2024;217(3):221–32.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ghermezi M, Li M, Vardanyan S, Harutyunyan NM, Gottlieb J, Berenson A, et al. Serum B-cell maturation antigen: a novel biomarker to predict outcomes for multiple myeloma patients. Haematologica. 2017;102(4):785–95.

Article  CAS  PubMed  Google Scholar 

Tai YT, Mayes PA, Acharya C, Zhong MY, Cea M, Cagnetta A, et al. Novel anti-B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma. Blood. 2014;123(20):3128–38.

Article  CAS  PubMed  PubMed Central  Google Scholar 

de Montes Oca R, Alavi AS, Vitali N, Bhattacharya S, Blackwell C, Patel K, et al. Belantamab mafodotin (GSK2857916) drives immunogenic cell death and immune-mediated antitumor responses in vivo. Mol Cancer Ther. 2021;20(10):1941–55.

Article  Google Scholar 

Kostopoulos IV, Kakalis A, Birmpilis A, Angelis N, Orologas-Stavrou N, Rousakis P, et al. Belantamab mafodotin induces immunogenic cell death within 24 h post-administration in newly diagnosed multiple myeloma patients. Am J Hematol. 2023;98(3):E65–7.

Article  CAS  PubMed  Google Scholar 

Trudel S, Lendvai N, Popat R, Voorhees PM, Reeves B, Libby EN, et al. Targeting B-cell maturation antigen with GSK2857916 antibody-drug conjugate in relapsed or refractory multiple myeloma (BMA117159): a dose escalation and expansion phase 1 trial. Lancet Oncol. 2018;19(12):1641–53.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lonial S, Lee HC, Badros A, Trudel S, Nooka AK, Chari A, et al. Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study. Lancet Oncol. 2020;21(2):207–21.

Article  CAS  PubMed  Google Scholar 

Trudel S, Lendvai N, Popat R, Voorhees PM, Reeves B, Libby EN, et al. Antibody-drug conjugate, GSK2857916, in relapsed/refractory multiple myeloma: an update on safety and efficacy from dose expansion phase I study. Blood Cancer J. 2019;9(4):37.

Article  PubMed  PubMed Central  Google Scholar 

Lonial S, Lee HC, Badros A, Trudel S, Nooka AK, Chari A, et al. Longer term outcomes with single-agent belantamab mafodotin in patients with relapsed or refractory multiple myeloma: 13-month follow-up from the pivotal DREAMM-2 study. Cancer. 2021;127(22):4198–212.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Dimopoulos MA, Hungria VTM, Radinoff A, Delimpasi S, Mikala G, Masszi T, et al. Efficacy and safety of single-agent belantamab mafodotin versus pomalidomide plus low-dose dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-3): a phase 3, open-label, randomised study. Lancet Haematol. 2023;10(10):e801–12.

Article  CAS  PubMed  Google Scholar 

Hungria VTM, Weisel K, Radinoff A, Delimpasi S, Mikala G, Masszi T, et al. P-395 updated results from DREAMM-3, a phase 3 study of belantamab mafodotin (Belamaf) versus pomalidomide plus dexamethasone in patients (pts) with relapsed/refractory multiple myeloma (RRMM). Clin Lymphoma Myeloma Leuk. 2024;24:S261–2.

Article  Google Scholar 

Mukhopadhyay P, Abdullah HA, Opalinska JB, Paka P, Richards E, Weisel K, et al. The clinical journey of belantamab mafodotin in relapsed or refractory multiple myeloma: lessons in drug development. Blood Cancer J. 2025;15(1):15.

Article  PubMed  PubMed Central  Google Scholar 

Hungria V, Robak P, Hus M, Zherebtsova V, Ward C, Ho PJ, et al. Belantamab mafodotin, bortezomib, and dexamethasone for multiple myeloma. N Engl J Med. 2024;391(5):393–407.

Article  CAS  PubMed  Google Scholar 

Hungria V, Robak P, Hus M, Zherebtsova V, Ward C, Ho PJ, et al. Belantamab mafodotin plus bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-7): updated overall survival analysis from a global, randomised, open-label, phase 3 trial. Lancet Oncol. 2025;26(8):1067–80.

Article  CAS  PubMed  Google Scholar 

Dimopoulos MA, Beksac M, Pour L, Delimpasi S, Vorobyev V, Quach H, et al. Belantamab mafodotin, pomalidomide, and dexamethasone in multiple myeloma. N Engl J Med. 2024;391(5):408–21.

Article  CAS  PubMed  Google Scholar 

Dimopolous MA, Beksac M, Pour L, Delimapsi S, Vorobyev V, Quach H, et al. MM-1045: updated results from the phase 3 DREAMM-8 Study of belantamab mafodotin (Belamaf) plus pomalidomide and dexamethasone (BPd) vs pomalidomide plus bortezomib and dexamethasone (PVd) in relapsed/refractory multiple myeloma. Clin Lymphoma Myeloma Leukemia. 2025;25:S959–60.

Shragai T, Magen H, Lavi N, Gatt M, Trestman S, Zektser M, et al. Real-world experience with belantamab mafodotin therapy for relapsed/refractory multiple myeloma: a multicentre retrospective study. Br J Haematol. 2023;200(1):45–53.

Article  CAS  PubMed  Google Scholar 

de la Rubia J, Alonso R, Clavero ME, Askari E, Garcia A, Anton C, et al. Belantamab mafodotin in patients with relapsed/refractory multiple myeloma: results of the compassionate use or the expanded access program in Spain. Cancers (Basel). 2023

Talbot A, Bobin A, Tabone L, Lambert J, Boccaccio C, Deal C, et al. Real-world study of the efficacy and safety of belantamab mafodotin (GSK2857916) in relapsed or refractory multiple myeloma based on data from the nominative ATU in France: the IFM 2020-04 study. Haematologica. 2023;108(10):2774–82.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Roussel M, Texier N, Nael V, Bitetti J, Paka P, Kerbouche N, et al. Effectiveness and safety of belantamab mafodotin in patients with relapsed or refractory multiple myeloma in real-world setting: the ALFA study. Eur J Haematol. 2024;113(3):310–20.

Article  CAS